Objective To investigate the serum levels and correlation between macrophage migration inhibitory factor (MIF) and regulated on activation normal T cell expressed and secreted cytokines (RANTES) in patients with chronic hepatitis B (CHB).Methods Forty-four CHB patients (CHB group)and 30 healthy controls (control group) were enrolled in this study.The venous blood was collected and serum MIF and RANTES levels were detected by enzyme-linked immunosorbent assay.Correlation between MIF and RANTES was analyzed in CHB group.Results The serum MIF and RANTES levels in CHB group were significantly higher than those in control group [(8.48 ± 1.70) μ g/L vs.(1.99 ± 2.38) μ g/L,(3.94 ±2.38) μ g/L vs.(0.33 ± 0.15) μ g/L,P =0.000].There was no correlation between MIF level and RANTES level(r =0.212,P＞ 0.05).Conclusions The serum MIF and RANTES levels are significantly increased in patients with CHB,but there is no correlation.The participation pathogenesis way of CHB is different.

OBJECTIVE: To explore the changes and clinical significance of saliva urea, creatinine (Cr), uric acid (UA) in both healthy people and chronic kidney disease (CKD) patients, and to provide a noninvasive, quick, accurate and reliable test to diagnose kindey disease. METHODS: Urea, Cr and UA in the saliva and serum collected from both healthy people and the CKD patients were measured by biochemical analyzer. We calculated the correlation coefficient of Urea, Cr and UA between the saliva and serum, compared the levels of saliva Urea, Cr and UA among CKD patients in different periods, drew the receiver operation characteristic (ROC) curve and analyzed the sensitivity and specificity of saliva Urea, Cr and UA to predict CKD patients in various periods. RESULTS: The concentrations of Urea, Cr and UA in both the saliva and the serum were positively correlated in healthy individuals and CKD patients (r = 0.918, 0.932, 0.840 and 0.984, 0.971, 0.920). The levels of saliva Urea, Cr and UA in the CKD patients were significantly higher than those of healthy people (P<0.05). Saliva Urea, Cr and UA concentrations of middle and late stage CKD patients were obviously higher than those of healthy people and early stage CKD patients (P<0.05). Areas under the curve (AUC) of the ROC of Urea, Cr and UA to diagnose diverse periods of CKD were 0.898, 0.897 and 0.848. The sensitivity was 0.806, 0.776 and 0.704; and the specificity was 0.968, 0.989 and 0.871. CONCLUSION The levels of Urea, Cr and UA between the saliva and the serum are closely related. The concentration of saliva Urea, Cr and UA can reflect the renal damage, monitor kidney function of the CKD patients, and help diagnose middle to late stage CKD patients. It is a simple, nonivasive and quick method.
Adolescent ; Adult ; Aged ; Case-Control Studies ; Creatinine ; analysis ; Female ; Humans ; Male ; Middle Aged ; Renal Insufficiency, Chronic ; metabolism ; Saliva ; chemistry ; Urea ; analysis ; Uric Acid ; analysis ; Young Adult

Objective To investigate expression and significance of serum interleukin-32 of patients with chronic hepatitis B (CHB) treated with different anti-viral drugs.Methods One hundred and eighty CHB patients were randomly divided into two groups.The first group included 92 CHB patients,who were orally treated with lamivudine (LAM) 100 mg+ ADV 10 mg,once daily.The second group included 88 CHB patients who were subcutaneously treated with interferon (IFN),180 μg,once a week.The treatment period was 48 weeks.Serum IL-32 expression of patients was tested by ELISA,and the difference in IL-32 expression between two groups was compared by using statistical methods.Then the correlations between IL-32 and alanine aminotranferase (ALT),aspartate aminotranferase (AST),total bilirubin (TBIL),HBV DNA were analyzed,respectively.Results Serum IL-32 expression of all patients gradually decreased after anti-viral treatment,but the difference in IL-32 expression between two groups was not statistically significant until weeks 48.Serum IL-32 expression was positively related with serum ALT,AST and HBV DNA load,respectively,and was not related with serum TBIL.Conclusion Serum IL-32 expression of CHB patients gradually decreased after anti-viral treatment.IL-32 might be involved in the pathogenesis of CHB.

Objective To compare the therapeutic effect between peginterferonα-2a and tel-bivudine (TLD)in treatment of patients with HBeAg positive chronic hepatitis B (CHB).Methods 71 patients with HBeAg positive CHB were divided into peginterferonα-2a group (n =33)and TLD group (n =38).Efficacy was compared and the HBeAg seroconversion factors were analyzed. Results 48 weeks after treatment,the negative conversion rates of serum HBV DNA in peginter-feronα-2a group and TLD group were 54.5% and 78.9% (P <0.05)respectively,the ALT nor-malization rates were 60.6% and 81.5% (P <0.05)respectively,the HBeAg seroconversion rates were 36.4% and 28.9% (P >0.05)respectively.There was no significant correlation between HBeAg seroconversion and ALT,HBV DNA HBeAg levels.The logistic regression analysis showed that the HBeAg seroconversion ratio in the peginterferonα-2a group at the 48th week was closely re-lated to 3 factors:the HBeAg decreased more than 2log at the 12th,24th and 36th week.The HBeAg seroconversion ratio in theTLDgroup at the4 8 thweekwas closely associatedwith 3 factors :the HBeAg decreased more than 2 log at the 3 6 th ,2 4 th and 1 2 th week .Conclusion The negative conversion rate of HBV DNA and ALT normalization rate in patients with HBeAg posi-tive CHB after 48 weeks therapy in TLD group are higher than those in peginterferonα-2a group. The HBeAg decreased more than 2log from the baseline to the 36th week can be used as the best predictor for the HBeAg seroconversion rate after the 48th week therapy in both groups.The HBeAg decreased more than 2log from the baseline to the 12th week can be used as the best pre-dictor for the HBeAg seroconversion rate after the 48th week therapy in the peginterferonα-2a group,and the HBeAg decreased more than 2log from the baseline to the 36th week can be used as the best predictor for the HBeAg seroconversion rate after the 48th week therapy in the TLD group.

Objective To compare the therapeutic effect between peginterferonα-2a and tel-bivudine (TLD)in treatment of patients with HBeAg positive chronic hepatitis B (CHB).Methods 71 patients with HBeAg positive CHB were divided into peginterferonα-2a group (n =33)and TLD group (n =38).Efficacy was compared and the HBeAg seroconversion factors were analyzed. Results 48 weeks after treatment,the negative conversion rates of serum HBV DNA in peginter-feronα-2a group and TLD group were 54.5% and 78.9% (P <0.05)respectively,the ALT nor-malization rates were 60.6% and 81.5% (P <0.05)respectively,the HBeAg seroconversion rates were 36.4% and 28.9% (P >0.05)respectively.There was no significant correlation between HBeAg seroconversion and ALT,HBV DNA HBeAg levels.The logistic regression analysis showed that the HBeAg seroconversion ratio in the peginterferonα-2a group at the 48th week was closely re-lated to 3 factors:the HBeAg decreased more than 2log at the 12th,24th and 36th week.The HBeAg seroconversion ratio in theTLDgroup at the4 8 thweekwas closely associatedwith 3 factors :the HBeAg decreased more than 2 log at the 3 6 th ,2 4 th and 1 2 th week .Conclusion The negative conversion rate of HBV DNA and ALT normalization rate in patients with HBeAg posi-tive CHB after 48 weeks therapy in TLD group are higher than those in peginterferonα-2a group. The HBeAg decreased more than 2log from the baseline to the 36th week can be used as the best predictor for the HBeAg seroconversion rate after the 48th week therapy in both groups.The HBeAg decreased more than 2log from the baseline to the 12th week can be used as the best pre-dictor for the HBeAg seroconversion rate after the 48th week therapy in the peginterferonα-2a group,and the HBeAg decreased more than 2log from the baseline to the 36th week can be used as the best predictor for the HBeAg seroconversion rate after the 48th week therapy in the TLD group.